Dear Editor, Uveal melanoma (UM) is the most common primary intraocular malignancy and can be categorized into prognostically significant subgroups based on a gene expression profile (GEP): class 1 tumors have a low risk and class 2 tumors have a high risk for metastasis [1] . One of the most common treatments for UM is Iodine-125 (I-125) episcleral plaque radiotherapy. To identify factors associated with response to radiotherapy, we studied a cohort of 281 consecutive UM patients who underwent GEP molecular classification at the time of plaque placement. The study was approved by the Institutional Review Board at the University of Miami. In this letter, we describe a distinct subset of nine (3 %) patients who demonstrated rapid tumor regression associated with transient tumor inflammation and uveitis (Fig. 1) . The patients included four women and five men, with a mean age of 54.1 years (median 54 years), mean initial tumor diameter of 13.3 mm (median 13.0 mm), and mean initial tumor thickness of 6.9 mm (median 6.6 mm). Remarkably, all nine of these patients had a class 1 primary uveal melanoma. Since 162 (58 %) patients from the entire cohort had a class 1 tumor, the likelihood of all nine (100 %) patients with acute inflammatory tumor regression having a class 1 tumor by chance is 1 in 1,000 (Fisher exact test).
Previous reports have linked rapid postradiation regression of uveal melanomas with a higher risk of metastastic disease [2] . More recent reports have found no association between postradiation regression rates and GEP prognostic class [3, 4] . However, none of these earlier studies identified a subset of patients described here with rapid tumor regression due to postradiation inflammatory response. Thus, our findings are not contradictory to earlier studies but describe a newly recognized subset.
Class 1 tumors are distinguished from class 2 tumors by their sustained expression of melanocytic differentiation antigens that are downregulated in the stem celllike class 2 tumors [5] . It is these differentiationassociated proteins that are most commonly recognized by the immune system in cases of successful immunotherapy in melanoma [6] . Although this study is limited by its retrospective design and small sample of patients with rapid regression, the results suggest that class 1 tumors may be more immunogenic than class 2 tumors following I-125 brachytherapy.
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